CAR NKT cells offer a promising novel immunotherapy for solid tumors

Oct 14, 2020

1 min read

Natural killer T (NKT) cells, a type of immune cells known for their potent anti-cancer properties in murine tumor models, have been developed into a novel form of immunotherapy to treat patients with cancer.

Comments

Unraveling how a deadly childhood cancer spreads could keep it in its place

Unraveling how immune aging influences health outcomes for survivors of childhood blood cancers

Unexpected discovery points to a possible route for childhood brain tumor treatments

Turning Pediatric Cancer Discoveries Into Medicines Requires Better Connections

Removing immune 'brake' improves CAR T-cell therapy for pediatric bone cancer

Cardiometabolic Risk in Childhood Cancer Survivors Treated With Anthracyclines

Hodgkin Lymphoma Survivors Face Higher Long-Term Mortality

Emotional health supports physical health in survivors of childhood cancer

Hidden aggressive cells reveal why some lower-risk childhood cancers turn deadly

Personalized T-cell therapy eliminates detectable metastatic kidney tumor in adolescent after multiple relapses

Recent Posts